NIH Clinical Research Studies Listed By Institute of the Principal Investigator

National Institute of Allergy and Infectious Diseases (NIAID)

155 Protocols (138 Active Accrual of new subjects, 17 Follow-up of previously enrolled subjects)


Active Accrual, Protocols Recruiting New Patients 
* 15-I-0001:
A Phase 1 Randomized, Double-Blind, Placebo Controlled, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of Prime-Boost VSV Ebola Vaccine in Healthy Adults

* 14-I-0206:
Novel Genetic Disorders of the Immune System

* 14-I-0199:
Human Immunity Against Staphylococcus Aureus Skin Infection

* 14-I-0194:
Screening of Volunteers for Clinical Trials of Investigational or Licensed Vaccines or Antiviral Products

* 14-I-0191:
NACC 002: A Multicenter Prospective Natural History Study of Patients Presenting with Neurocysticercosis in North America

* 14-I-0185:
A Phase III Double-Blind Randomized Crossover Study of Plerixafor Versus G-CSF in the Treatment of Patients with WHIM Syndrome.

* 14-I-0183:
VRC 207: A Phase I/1b, Open-Label, Dose-Escalation Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Ebola Chimpanzee Adenovirus Vector Vaccines, VRC-EBOADC069-00-VP (cAd3-EBO) and VRC-EBOADC076-00-VP (cAd3-EBOZ), in Healthy A

* 14-I-0178:
Longitudinal Study of Immune Responses to Mycobacterium Tuberculosis (Mtb) in Subjects with Latent Tuberculosis (TB) Infection(LTBI) With or Without Concomitant Helminth Infection

* 14-I-0160:
VRC 315: A Phase I Open-Label, Randomized Study of H7 Influenza Prime-Boost Regimens in Healthy Adults: Recombinant H7 DNA Plasmid Vaccine, VRC-FLUDNA071-00-VP, Administered Alone or with Monovalent Influenza Subunit Virion H7N9 Vaccine (MIV) as Prime wi

* 14-I-0153:
An Open-Label Phase I Pilot Study to Assess the Safety/Tolerability and Efficacy of Ustekinumab for Symptomatic Gastrointestinal Inflammation Associated with Common Variable Immunodeficiency

* 14-I-0146:
The Pathogenesis and Genetics of Disseminated or Refractory Coccidiodomycosis

* 14-I-0124:
PET Imaging and Lymph Node Assessment of IRIS in Persons With AIDS

* 14-I-0121:
Longitudinal Analysis of Plasmodium Falciparum-Specific Immunity in Travelers and Immigrants from Malaria Endemic Areas to the United States

* 14-I-0115:
A Double-blind, Randomized, Placebo-controlled Study to Investigate the Efficacy and Safety of Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis (EGPA) in Subjects Receiving Standard of Care Therapy

* 14-I-0089:
A Retrospective and Cross-Sectional Analysis of Patients Treated for Severe Combined Immunodeficiency (SCID) Since January 1, 1968

* 14-I-0081:
A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Subcutaneous Benralizumab (MEDI-563) in Reducing Eosinophilia in Subjects with Hypereosinophilic Syndrome (HES)

* 14-I-0072:
A Prospective Natural History Study of Diagnosis, Treatment and Outcomes of Children with SCID Disorders

* 14-I-0063:
An Open-Label, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Dexpramipexole (KNS-760704) in Subjects with Hypereosinophilic Syndrome

* 14-I-0050:
Imaging CXCR4 Expression in Subjects With Cancer Using 64 Cu-Plerixafor

* 14-I-0043:
A Phase 1, Open Label, Ascending Dose Cohort Study of the Pharmacokinetics of Anti-Influenza Hyperimmune Intravenous Immunoglobulin in Healthy Subjects

* 14-I-0039:
Elite Controller and ART-Treated HIV+ Statin Versus ASA Treatment Intervention Study

* 14-I-0035:
VRC 314: A Phase 1, Open-Label, Clinical Trial with Experimental Controlled Human Malaria Infections (CHMI) to Evaluate Safety and Durability of Protection Following Intravenous and Intramuscular Administration of PFSPZ Vaccine in Malaria-Naive Adults

* 14-I-0031:
Anti-Influenza Hyperimmune Intravenous Immunoglobulin Pilot Study(Flu-IVIG Pilot)

* 14-I-0020:
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

* 14-I-0019:
VRC 602: A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIV MAB060-00-AB (VRC01),Administered Intravenously or Subcutaneously to Healthy Adults

* 14-I-0011:
Phase I Study of Safety and Immunogenicity of Ad4-HIV Vaccine Vectors in Healthy Volunteers

* 14-I-0009:
Characterization and Management of Patients with HIV-1 Infection Who Experience Virologic Failure Despite Combination Antiretroviral Therapy

* 13-I-0215:
Evaluation of Anti-Hemagglutinin Antibodies as a Correlate of Protection in an H1N1 Influenza Healthy Human Challenge Model

* 13-I-0189:
VRC 601: A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC HIVMAB060-00-AB (VRC01), with Broad HIV-1 Neutralizing Activity, Administered Intravenously or Subcutaneously to HIV-Infected Adu

* 13-I-0181:
Microbiomic and Immunologic Profiling of Women with Antibiotic induced Vaginal Candidiasis

* 13-I-0177:
Natural History Study of the Complications Associated with Allogeneic Hematopoietic Stem Cell Transplantations

* 13-I-0172:
Phase I Study of the Safety of Replication-Defective Herpes Simplex Virus-2 Vaccine, HSV529, in Adults Aged 18 to 40 Years With or Without HSV Infection

* 13-I-0157:
The Natural History of GATA2 Deficiency

* 13-I-0141:
A Phase I Randomized, Double-Blind, Placebo-Controlled Study of a Multi-Antigen DNA Vaccine Prime Delivered by In Vivo Electroporation, rVSV Booster Vaccine in HIV-Infected Patients Who Began Antiretroviral Therapy During Acute/Early Infection

* 13-I-0117:
Radiofrequency Ablation (RFA) for the Treatment of Liver Abscesses in Patients with Chronic Granulomatous Disease

* 13-I-0094:
A Phase 1, Open-Label Study of Sirolimus in Eosinophil-Associated Gastrointestinal Disorders

* 13-I-0082:
Rituximab (Anti-CD20) for the Treatment of Subjects With Anticytokine Autoantibody-Associated Diseases

* 13-I-0081:
Phase 1 Study of Safety and Immunogenicity of Intranasal Ad4-H5-VTN in Ad4 Seronegative and Seropositive Volunteers

* 13-I-0077:
An Open-Label, Phase 1 Study to Assess the Safety and Tolerability of Bone Marrow Stromal Cell Infusion for the treatment of Moderate to Severe Inflammatory Bowel Disease

* 13-I-0066:
A Pilot Study to Evaluate the Safety and Efficacy of Multiple Anti-HCV Combination Therapy in Chronically Infected Hepatitis C Patients

* 13-I-0062:
A Double Blind Randomized Placebo Controlled Study Examining the Effects of a Non-Absorbable (Rifaximin) Antibiotic on the Chronic Immune Activation Observed In HIV-infected Subjects

* 13-I-0029:
A Phase 1, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of AVI-7100 in Healthy Subjects

* 12-I-0184:
Use of Fluorodeoxyglucose Positron Emission Tomography with Computed Tomography for the Evaluation of Autoimmune Lymphoproliferative Syndrome Lymphadenopathy Suggestive of Lymphoma

* 12-I-0157:
Clinical Outcomes in Persons with HIV Acquired Early in Life

* 12-I-0142:
Transcriptional Signature of HIV And TB Co-Infection

* 12-I-0133:
A Randomized, Double-Blind, Placebo Controlled Study of Liposomal Amikacin for Inhalation (Arikace ) in Patients with Recalcitrant Nontuberculous Mycobacterial Lung Disease

* 12-I-0121:
Screening of Volunteers for Clinical Trials of Investigational and Licensed Vaccines, Antiviral Products, or Live Virus Challenge Studies

* 12-I-0026:
Assessment of Glucocorticoid Responsiveness and Mechanisms of Resistance in Hypereosinophilic Syndromes

* 11-I-0259:
Phase 1 Study of Safety and Immunogenicity of Ad4-H5-VTN in Ad4 Seronegative and Seropositive Volunteers

* 11-I-0187:
The Natural History and Pathogenesis of Human Fungal Infections

* 11-I-0183:
Screening of Volunteers for Influenza Human Challenge Studies

* 11-I-0164:
VRC 500:Screening of Volunteers for Clinical Trials of Investigational Products and Licensed Products Evaluated for Research Purposes

* 11-I-0109:
Viral Infections in Healthy and Immunocompromised Hosts

* 11-I-0057:
Effect of Interferon Alpha 2b Intensification on HIV-1 Residual Viremia in Individuals Suppressed on Antiretroviral Therapy

* 11-I-0031:
A Randomized Double-Blind Study Comparing Oseltamivir Versus Placebo for the Treatment of Influenza in Low Risk Adults

* 11-I-0007:
Lentiviral Gene Transfer for Treatment of Children Older Than 2 Years of Age with X-Linked Severe Combined Immunodeficiency

* 10-I-0216:
Studies of Disorders with Increased Susceptibility to Fungal Infections

* 10-I-0210:
A Randomized Double-Blind Phase 2 Study Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir versus Oseltamivir for the Treatment of Influenza in Adults at Risk for Complications

* 10-I-0205:
Assessment of Alterations in Immune Function During Pregnancy and Post Parturition

* 10-I-0197:
Admission and Management of Occupational or Other Exposures to Biodefense/Bioterrorism Agents or to Epidemic/Emerging Infectious Diseases

* 10-I-0196:
Immunopathogenesis of Food Allergy and Eosinophilic Gastrointestinal Disorders

* 10-I-0195:
Training Protocol on the Natural History of Tuberculosis

* 10-I-0148:
Natural History of Atopic Dermatitis and Other Genetic/Congenital Diseases Associated with Allergic Inflammation

* 10-I-0139:
Searching for Persistence of Infection in Lyme Disease

* 10-I-0123:
Assessment of the Biochemical Response to Interferon-Gamma in Subjects with Specific Gene Mutation in Chronic Granulomatous Disease

* 10-I-0109:
VRC 900: Evaluation of Tissue-Specific Immune Responses in Adults 18 Years of Age and Older

* 10-I-0101:
A Randomized, Placebo-controlled, Double-Blind Pilot Study of Single-Dose Humanized Anti-IL5 Antibody (Reslizumab) for the Reduction of Eosinophilia Following Diethylcarbamazine Treatment of Loa Loa Infection

* 10-I-0095:
Collection of Peripheral Blood Stem Cells Using G-CSF and Plerixafor in Normal Volunteers

* 10-I-0043:
A Randomized, Open-Label, Phase 2, Multicenter Safety and Exploratory Efficacy Study of Investigational anti-Influenza Immune Plasma for the Treatment of Influenza

* 10-I-0029:
Non-Invasive Assessment of Atherosclerosis in Patients with CGD and Other Disorders of the Immune System

* 10-I-0014:
The Natural History of Severe Viral Infections and Characterization of Immune Defects

* 09-I-0246:
A Phase II, Open Label Trial of a Vaccine (FSME-IMMUN 0.5 mL Baxter) Against Tick-Borne Encephalitis (TBE) for NIAID Workers Manipulating Tick-Borne Encephalitis Virus (TBEV) in the Laboratory

* 09-I-0232:
An International Observational Study to Characterize Adults Who Are Hospitalized with Complications of Influenza

* 09-I-0200:
A Phase I Study of Mozobil (TM) in the Treatment of Patients with WHIMS

* 09-I-0184:
Studies in the Pathogenesis of Systemic Capillary Leak Syndrome

* 09-I-0172:
Natural History of Bronchiectasis

* 09-I-0133:
Establishing Fibroblast-derived Cell Lines from Skin Biopsies of Patients with Immunodeficiency or Immunodysregulation Disorders

* 09-I-0129:
A Randomized Double-Blinded, Placebo-Controlled Study of Omalizumab for Idiopathic Anaphylaxis

* 09-I-0126:
Pathogenesis of Physical Induced Urticarial Syndromes

* 09-I-0102:
Etiology, Pathogenesis, and Natural History of Idiopathic CD4+ Lymphocytopenia

* 09-I-0086:
Screening Protocol for Genetic Diseases of Allergic Inflammation and Mast Cell Homeostasis and Activation

* 09-I-0049:
Normal Blood, Bone Marrow and Buccal Mucosa Protocol

* 09-I-0030:
Clinical and Immunologic Monitoring of Patients with Known or Suspected HIV Infection

* 09-I-0013:
Biomarkers of Inflammation, Coagulation, and Endothelial Function in HIV-Infected Adults

* 08-I-0221:
Analysis of HIV-1 Replication During Antiretroviral Therapy

* 08-I-0184:
Studies in the Pathogenesis of Idiopathic Anaphylaxis

* 07-I-0229:
Influenza in the Non-immunocompromised and Immunocompromised Host

* 07-I-0183:
The Collection of Research Samples and/or Data for Repository from Related or Unrelated Hematopoietic Stem Cell Transplantation Recipients for the National Marrow Donor Program

* 07-I-0142:
Research Respiratory Tract Procedures

* 07-I-0075:
Allogeneic and Matched Unrelated Donor Stem Cell Transplantation for Congenital Immunodeficiencies or Patients with Autoinflammatory/Immunodysregulatory Conditions: Busulfan-Based Conditioning with Campath- 1H or h-ATG, Radiation, and Sirolimus

* 07-I-0033:
Screening Protocol for Detection and Characterization of Infections and Infection Susceptibility

* 06-I-0153:
A Pilot Study of Hepatic Fibrosis in HIV/AIDS Patients with Chronically Elevated Transaminases on Antiretroviral Therapy

* 06-I-0015:
Screening Protocol for Genetic Diseases of Lymphocyte Homeostasis and Programmed Cell Death

* 05-I-0219:
Microarray Analysis of Erythema Migrans Lesions

* 05-I-0213:
Screening and Baseline Assessment of Patients with Abnormalities of Immune Function

* 04-I-0286:
A Longitudinal Study of Familial Hypereosinophilia (FE): Natural History and Markers of Disease Progression

* 04-I-0266:
Collection of Peripheral Blood, Urine, Sputum, and Bone Marrow From Healthy Donors for Use in In Vitro Research

* 04-I-0086:
Evaluation of Clinical, Virologic and Immunologic Factors that Contribute to the Pathogenesis of Chronic Hepatitis C and its Complications

* 03-I-0263:
VRC 200: Apheresis and Specimen Collection Procedures to Obtain Plasma, Peripheral Blood Mononuclear Cells (PBMCs) and Other Specimens for Research Studies

* 02-I-0286:
A Pilot Study of the Safety and Efficacy of Imatinib Mesylate in Reducing Eosinophilia in Patients with the Myeloproliferative Variant Hypereosinophilic Syndrome (HES) or Non-Myeloproliferative HES Refractory to Standard Therapy

Next 55 Protocols

Command Menu Bar

Search The Studies | Help | Questions |
Clinical Center Home | NIH Home


Clinical Center LogoNational Institutes of Health Clinical Center
Bethesda, Maryland 20892. Last update: 10/25/2014

Search The Studies Help Questions
Search The Studies Help Questions